atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
Pharma marketing is constantly changing and #AI is helping to reshape how brands connect with their audiences.
Discover Medico Digital top 5 #AI predictions and learn how harnessing the power of AI can boost your marketing strategy. Read more here.
Luscii provides the tools for patient and professional to keep an eye on the recovery while checking vital signs and symptoms to signal deteriorations and intervene timely in case of need.
Read more here.
Attendees
Sponsors and Exhibitors
Media
Contact us